Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics
ACS Pharmacology & Translational Science · 11.10.2024 · 7 (10) · 2924-2935
DOI: 10.1021/acsptsci.4c00229 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Pharmacology & Translational Science, online erschienen am 06.09.2024. Verfasst von Ben Boyarko und 11 weiteren Autor:innen. Beteiligte Einrichtung: Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, Epstein Family Research Collaboration Award.
Themen: Demenz
Abstract (Originalsprache)
Therapeutic research and development for Alzheimer's disease (AD) has been an area of intense research to alleviate memory loss and neurodegeneration. There is growing interest in drug repositioning and repurposing strategies for FDA-approved medications as potential candidates that may further advance AD therapeutics. The FDA drug efavirenz has been investigated as a candidate drug for repurposing as an AD medication. The proposed mechanism of action of efavirenz (at low doses) is the activation of the neuron-specific enzyme CYP46A1 that converts excess brain cholesterol into 24-hydroxycholesterol (24-HC) that is exported to the periphery. Efavirenz at a low dose was found to improve memory deficit in the 5XFAD model of AD that was accompanied by elevated 24-HC and reduction in Aβ; furthermore, efavirenz reduced pTau and excess cholesterol levels in human iPSC-derived Alzheimer's neurons. The low dose of efavirenz used in the AD mouse model to increase 24-HC contrasts with the use of more than 100-fold higher doses of efavirenz for clinical treatment of human immunodeficiency virus (HIV) through inhibition of reverse transcriptase. Low doses of efavirenz may avoid neurotoxic adverse effects that occur at high efavirenz doses used for HIV treatment. This review evaluates the drug properties of efavirenz with respect to its preclinical data on regulating memory deficit, pharmacokinetics, pharmacodynamics, metabolites, and genetic variabilities in drug metabolism as well as its potential adverse effects. These analyses discuss the challenges and questions that should be addressed in future studies to consider the opportunity for low dose efavirenz as a candidate for AD drug development.
Autor:innen und Institutionen
- Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, California 92093, United States.
- Alzheimer's Disease Cooperative Study, School of Medicine, University of California, San Diego, La Jolla, California 92093, United States.
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States.
- Alzheimer's Clinical and Translational Research Unit, Massachusetts General Hospital, Charlestown, Massachusetts 02129, United States.
- Department of Functional Genomics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, VU University Amsterdam de Boelelaan, Amsterdam 1081 HV, The Netherlands.
- Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, California 92093, United States.
ORCID-Profile: Vivian Hook
Förderung
- NINDS NIH HHS
- Epstein Family Research Collaboration Award
Zitieren
APA
Boyarko, B., Podvin, S., Greenberg, B., Arnold, S., Juanes, A. M., van der Kant, R., Goldstein, L., Momper, J. D., Bang, A., Silverman, J., Feldman, H. H., & Hook, V. (2024). Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics. ACS Pharmacology & Translational Science, 7(10), 2924-2935. https://doi.org/10.1021/acsptsci.4c00229
Vancouver
Boyarko B, Podvin S, Greenberg B, Arnold S, Juanes AM, van der Kant R, et al. Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics. ACS Pharmacology & Translational Science. 2024;7(10):2924-2935. doi:10.1021/acsptsci.4c00229
BibTeX
@article{Boyarko2024,
author = {Boyarko, Ben and Podvin, Sonia and Greenberg, Barry and Arnold, Steven and Juanes, Almudena Maroto and van der Kant, Rik and Goldstein, Lawrence and Momper, Jeremiah D and Bang, Anne and Silverman, James and Feldman, Howard H and Hook, Vivian},
title = {Challenges and Opportunities for Consideration of Efavirenz Drug Repurposing for Alzheimer’s Disease Therapeutics},
journal = {ACS Pharmacology & Translational Science},
year = {2024},
volume = {7},
number = {10},
pages = {2924--2935},
doi = {10.1021/acsptsci.4c00229}
}
EUVIMED